Neurizon Therapeutics Limited has released a press release.
Epichem Successful in AusTrade Grant
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Appendix 4C Quarterly Report & Brief Company Update
- First Two Patients in Canine Clinical Trial Begin Treatment
- Completion of Share Sale Agreement and Drilling Commenced
- Placement & Offer to Purchase Pela Resources
- PharmAust to acquire rights to 3 oncology product platforms
Later from Neurizon Therapeutics
- University of Cambridge to begin Phase II Trial
- Reformulated MPL capsules completed, Phase II to commence
- Appendix 4C Quarterly & Brief Company Update - June 2016
- IP exchange with UNSW consolidates MPL patent position
- Further Canine Trials to be Initiated in Australia
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics